6 / 19
allied
academies
Page 24
Note:
Journal of Systems Biology & Proteome Research
|
Volume 2
J u n e 2 5 - 2 7 , 2 0 1 8 | D u b l i n , I r e l a n d
MASS SPECTROMETRY
AND PROTEOMICS
International Conference on
Serhiy Souchelnytskyi, J Syst Biol Proteome Res 2018, Volume 2
MASS SPECTROMETRY IN THE
WORKFLOW OF PERSONALIZED
CANCER TREATMENT: EVALUATION
OF PROTEIN EXPRESSION, PTMS AND
ACTIVITY
Serhiy Souchelnytskyi
Qatar University, Qatar
H
igh sensitivity has firmly established mass spectrometry as the method
of choice for identification and analysis of proteins. Clinical challenge of
personification of anti-cancer treatment requires analysis of small quantities
of proteins. There are more than 300 PTMs which affect functions of proteins,
and mass spectrometry is so far the most efficient in their identification.
All anti-cancer drugs act on or via proteins. Therefore, proteome analysis
is essential for efficient diagnostic and selection of treatment. In my
presentation, I will show examples of how we use mass spectrometry in our
efforts of personalization of cancer treatment. Expression proteomics, with
detection and identification of targets for potential anti-cancer treatment,
is one of the examples. Another example is mass spectrometry imaging in
combination with magnetic resonance imaging, to monitor responsiveness
of cancer cells to treatment. Study of breast and renal cancer cells will be
presented as examples. Unbiased detection of >30 PTMs in the same
proteins from cancer vs normal cells will also be discussed in the context of
tumorigenesis. Have mass spectrometry reached its limits? With a resolution
of >0.0001 Da, an impact may have such phenomena as mass vs energy
transformation. Isotope distribution in samples is another technical issue
which may influence results. These technical aspects will also be discussed.
Serhiy Souchelnytskyi graduated from Lviv
State University (1985) and obtained PhD de-
gree at the Institute of Biochemistry (1992) in
Lviv, Ukraine. He worked at the Institute of Bio-
chemistry (Ukraine), INSERM U244 (France),
Ludwig Institute for Cancer Research (Uppsala,
Sweden), Karolinska Institutet and Karolinska
University Hospital (Stockholm, Sweden), before
joining Qatar University in 2015. He is involved
in commercialization of research by develop-
ing diagnostic and personalization of cancer
treatment. He has 125 publications, including 5
patents. He is involved in editorial works as an
Editor and a member of Editorial boards, works
frequently for granting agencies as an expert,
and has received awards in the area of proteom-
ics and cancer biology. Current projects are in
development of personalized cancer medicine.
Proteomics, systems biology and cancer signal-
ing biology are used for individualized profiling
of patients, their diagnostic and selection of the
most efficient treatment.
serhiy@qu.edu.qaBIOGRAPHY